Gyon Technologies Capital Management, LP Biomarin Pharmaceutical Inc Transaction History

Gyon Technologies Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $781,217 - $1.05 Million	9,653 Added 150.22%	16,079 $1.66 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $993,314 - $1.17 Million	-12,090 Reduced 65.29%	6,426 $545,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $1.32 Million - $1.61 Million	18,516 New	18,516 $1.53 Million
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $736,634 - $919,206	-9,917 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $711,247 - $907,107	9,917 New	9,917 $876,000
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $271,045 - $328,932	-3,627 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $188,350 - $233,978	-2,594 Reduced 41.7%	3,627 $318,000
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $447,103 - $815,137	6,221 New	6,221 $473,000
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $1.43 Million - $1.94 Million	-20,049 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $1.29 Million - $1.73 Million	20,049 New	20,049 $1.7 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.